[1]. Jones CK, et al. The metabotropic glutamate receptor 4-positive allosteric modulator VU36477 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 212 Feb;34(2):44-21.
[1]. Jones CK, et al. The metabotropic glutamate receptor 4-positive allosteric modulator VU36477 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 212 Feb;34(2):44-21.